These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 34825867

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
    Derogis PB, Sanches LR, de Aranda VF, Colombini MP, Mangueira CL, Katz M, Faulhaber AC, Mendes CE, Ferreira CE, França CN, Guerra JC.
    PLoS One; 2017; 12(2):e0171272. PubMed ID: 28170419
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.
    Wiesen MHJ, Blaich C, Taubert M, Jennissen V, Streichert T, Pfister R, Michels G.
    Eur J Clin Pharmacol; 2018 May; 74(5):611-618. PubMed ID: 29376194
    [Abstract] [Full Text] [Related]

  • 5. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
    Horinaka S, Sugawara R, Yonezawa Y, Ishimitsu T.
    Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
    [Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
    Al-Aieshy F, Malmström RE, Antovic J, Pohanka A, Rönquist-Nii Y, Berndtsson M, Al-Khalili F, Skeppholm M.
    Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations.
    Wu T, Wu S, Li M, Zhang J.
    Ann Pharmacother; 2024 Jan; 58(1):28-36. PubMed ID: 37125735
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
    Yates SG, Smith S, Tharpe W, Shen YM, Sarode R.
    Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
    Willekens G, Studt JD, Mendez A, Alberio L, Fontana P, Wuillemin WA, Schmidt A, Graf L, Gerber B, Bovet C, Sauter TC, Nagler M.
    Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study.
    Li Y, Du L, Tang X, Chen Y, Mei D.
    BMC Pharmacol Toxicol; 2020 May 28; 21(1):38. PubMed ID: 32466800
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
    Liu Z, Xie Q, Zhang H, Mu G, Zhou S, Wang Z, Jiang J, Xiang Q, Cui Y.
    Am J Cardiovasc Drugs; 2021 Nov 28; 21(6):669-679. PubMed ID: 34142346
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.